NCT00240565

Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

A Single Arm, Open-label, Multicentre, Phase II Study of Tositumomab and Iodine 131-Tositumomab in Subjects With Indolent Non-Hodgkin's Lymphoma Who Have Previously Received Rituximab.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 93 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will further characterize the activity of Tositumomab and Iodine I 131-Tositumomab in patients with relapsed indolent non-Hodgkin's Lymphoma who have progressed following treatment with rituximab.

Conditions

• Lymphoma, Non-Hodgkin

Interventions

Type	Name	Description
DRUG	Tositumomab 450 mg	Unlabeled TST
DRUG	Tositumomab 35 mg	TST labeled with 185 megaBecqueral (mbq) of iodine 131

Timeline

• Start date: 2004-04-01
• Primary completion: 2007-02-01
• Completion: 2011-09-01
• First posted: 2005-10-18
• Last updated: 2012-08-13

Locations

11 sites across 1 country: Canada